Intelligence / Healthtech / New Clinical Trials / Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.
Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.
17 Nov 2026: Trial registered · A Study of HW201877 Capsules for Participants With Moderate to Severe Active Inflammatory Bowel Disease (IBD). Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 17 Nov 2026
- Title
- A Study of HW201877 Capsules for Participants With Moderate to Severe Active Inflammatory Bowel Disease (IBD)
- Conditions
- Inflammatory Bowel Disease (IBD)
- Phase
- Phase 2
- Study Type
- Interventional
- Status
- Not Yet Recruiting
- Countries
- China
- Country
- China
- Reference
- NCT07942766
- Location
- China
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Find the decision makers at Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
Across AOS Research
Other records for Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. in our registers.
More from China
New Clinical Trials
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.